[HTML][HTML] Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final …
SF Powell, MJ Hochmair, S Gadgeel, E Esteban… - Annals of …, 2021 - Elsevier
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from …
D Rodríguez-Abreu, SF Powell… - Annals of Oncology …, 2021 - europepmc.org
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly …
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from …
D Rodríguez Abreu, SF Powell, MJ Hochmair… - Annals of …, 2021 - accedacris.ulpgc.es
Background: In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly …
[引用][C] Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final …
D Rodríguez-Abreu, SF Powell, MJ Hochmair… - Annals of …, 2021 - cir.nii.ac.jp
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated
metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 | CiNii …
metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 | CiNii …
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from …
D Rodríguez-Abreu, SF Powell, MJ Hochmair… - 2021 - pubmed.ncbi.nlm.nih.gov
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly …
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from …
D Rodriguez-Abreu, SF Powell, MJ Hochmair… - 2021 - wslhd.intersearch.com.au
Background: In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly …
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from …
D Rodríguez-Abreu, SF Powell… - Annals of …, 2021 - annalsofoncology.org
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from …
D Rodríguez-Abreu, SF Powell, MJ Hochmair… - Annals of …, 2021 - hub.hku.hk
Background: In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …